Introduction
============

Lung cancer is the leading cause of cancer-related deaths for patients worldwide, with the highest incidence rates among all malignancies. For the purposes of treatment, lung cancer is classified into several histological subtypes, including small cell lung cancer (13% of cases) or non-small cell lung cancer (NSCLC, 83% of cases) ([@b1-mmr-21-01-0360],[@b2-mmr-21-01-0360]). In most countries, lung adenocarcinoma (LUAD) is the most frequent histological NSCLC subtype. Despite comprehensive treatment in clinical practice, most LUAD patients at present are commonly diagnosed at late stages, and meanwhile receive insufficient treatment efficacy ([@b3-mmr-21-01-0360]). Therefore, identification of the novel biomarkers and molecular events associated with LUAD biology would provide novel insights for developing a more rational therapeutic strategy.

Pyroptosis is a form of gasdermin (GSDM)-mediated programmed necrosis that is essential for multicellular organism development and immune response. The members of the GSDM superfamily (GSDMA, GSDMB, GSDMC, GSDMD, DFNA5 and DFNB59) share a similar pore-forming domain in their crystal structure, which is critical to execute pyroptosis induction ([@b4-mmr-21-01-0360]--[@b6-mmr-21-01-0360]). Recently, various studies have revealed the dysfunction and abnormal expression of the GSDM family in multiple human cancers ([@b7-mmr-21-01-0360],[@b8-mmr-21-01-0360]), implying the potential roles in tumorigenesis. Moreover, the clinical application of the GSDM family as diagnostic and prognostic factors for cancer patients is to be further elucidated in detail. Using high-resolution melting curve analysis, Lutkowska *et al* ([@b7-mmr-21-01-0360]) found that a single nucleotide polymorphism (SNP) variant, rs8067378, significantly increased the expression of *GSDMB*, further leading to cervical carcinogenesis. Miguchi *et al* ([@b8-mmr-21-01-0360]) demonstrated that *GSDMC*, functioning as a promising oncogene, promoted cell proliferation in colorectal cancer by depressing TGFBR2 (transforming growth factor β receptor type II) activation. However, the potential functions and detailed mechanisms of the GSDM family in lung cancer are still unknown.

The present study was conducted to explore the detailed function and molecular mechanism of the GSDM family in LUAD biology. Using data from several bioinformatic platforms, the expression profiles of GSDM family members were evaluated in LUAD cases. *GSDMC* was found to be significantly upregulated in LUAD samples. Moreover, data from Kaplan-Meier curves showed that upregulated *GSDMC* acts as a negative prognostic indicator for LUAD patients. Mechanistically, based on data from The Cancer Genome Atlas (TCGA) database, the effect of DNA methylation value of *GSDMC* on its expression and prognostic value were evaluated in LUAD patients. Meanwhile, the copy number alterations (CNAs) and mutation status of *GSDMC* DNA were also explored to further investigate *GSDMC* dysregulation in LUAD.

Materials and methods
=====================

### Reanalysis of the acquisition data

The molecular profiles of GSDM family members in LUAD tissues and cell lines were identified from multiple bioinformatic platforms, such as Gene Expression Profiling Interactive Analysis (GEPIA), UALCAN and Oncomine. GEPIA is an online tool for gene expression profiling analyses in cancer and adjacent tissues ([@b9-mmr-21-01-0360]). UALCAN platform is helpful for in-silico validation of tumor subgroup candidate biomarkers ([@b10-mmr-21-01-0360]). Serving as a cancer microarray data-mining platform, Oncomine is valuable to characterize the gene expression signatures in multiple human cancer tissues and cells ([@b11-mmr-21-01-0360]). The Cancer Cell Line Encyclopedia (CCLE) project provides public access for the systematic exploration of genetic and pharmacologic characterization in approximately 1,457 cell lines ([@b12-mmr-21-01-0360]). The Human Protein Atlas Project, an international program, has been set up to draw a map of protein signatures on a cellular level ([@b13-mmr-21-01-0360]). Using these bioinformatics data, the molecular profiles of the GSDM family were definitely characterized in LUAD patients.

Several bioinformatic tools, such as cBioPortal ([@b14-mmr-21-01-0360]) and Kaplan-Meier Plotter ([@b15-mmr-21-01-0360]), were used to reanalyze the clinical significance of *GSDMC* in LUAD cancer cases by linking TCGA clinical data to mRNA expression and DNA methylation values. In particular, using a TCGA-LUAD dataset (TCGA, Provisional) from cBioPortal, a retrospective study was performed to evaluate the association between *GSDMC* molecular profiles and clinical pathologic characteristics in LUAD patients. MethHC ([@b16-mmr-21-01-0360]) and MEXPRESS ([@b17-mmr-21-01-0360]) are two web databases that focus on the methylomes of human diseases, databases through which we confirmed the different methylation values between cancerous and noncancerous tissues. An important characteristic of MethHC and MEXPRESS is that all figures offer not just a visualization of the findings, but also a statistical analysis. The figures show the P-values and Pearson correlation coefficients for the comparison between the methylation value and expression level of the corresponding genes. The Kaplan-Meier algorithm was used to analyze the disease prognostic markers, such as first progression (FP), overall survival (OS) and postprogression survival (PPS). As for the Kaplan-Meier Plotter and DNA methylation analyses, all possible cut-off values between the lower and upper quartiles were analyzed by the algorithm automatically, and the best performing threshold was used as an optimal cut-off.

Subsequently, the copy number alterations (CNAs) and mutation status of *GSDMC* DNA were also downloaded from the cBioPortal web-server to re-analyze the potential roles of *GSDMC* in LUAD tumorigenesis.

In addition, we selected the abovementioned TCGA-LUAD dataset (TCGA, Provisional), which contained 517 RNA-sequenced samples, to analyze the coexpression genes of *GSDMC*. Using SangerBox tools, a Volcano Plot was drawn for a detailed visualization of differentially expressed genes (DEGs), with the criteria of \|log~2~ (fold change)\| ≥2 and P-value \<0.05. Moreover, the functional enrichment analysis of these DEGs, including Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, was performed using Database for Annotation, Visualization and Integration Discovery (DAVID) ([@b18-mmr-21-01-0360]). The visualization of GO terms was showed by a web platform, WEB-based Gene SeT AnaLysis Toolkit (WebGestalt) ([@b19-mmr-21-01-0360]).

All bioinformatic tools mentioned above are summarized in [Table I](#tI-mmr-21-01-0360){ref-type="table"}.

### Cell lines

The LUAD cell lines NCIH358 (ATCC CCL-5807), A549 (ATCC CCL-18), and their corresponding radio-resistant cells (NCIH358R and A549R) were kindly provided by the laboratory of Professor Deng (Winship Cancer Institute of Emory University, USA) ([@b20-mmr-21-01-0360],[@b21-mmr-21-01-0360]), and maintained in DMEM/F-12 medium (Hyclone) containing 10% fetal bovine serum (FBS) and 1% penicillin/gentamicin/streptomycin at 37°C with 5% carbon dioxide.

### Real-time fluorescence quantitative PCR

As previously described ([@b22-mmr-21-01-0360]), the total RNA was extracted from LUAD cells and used for cDNA synthesis. Real-time fluorescence quantitative PCR (qPCR) was performed using the CFX96 Touch Real-Time PCR Detection System (Bio-Rad) with Applied Biosystems Power SYBR Green PCR Master Mix (cat. no. 4367659, Thermo Fisher Scientific, Inc.). Amplification was performed in a three-step cycle procedure (denaturation at 95°C for 1 sec, ramp rate 20°C/sec; annealing at 60°C for 10 sec, ramp rate 20°C/sec; and extension at 72°C for 26 sec, ramp rate 2°C/sec) for 40 cycles. The involving primers were as follows: *GSDMC* forward, 5′-TCCGAAATGGTAGGCTACTGT-3′ and reverse, 5′-ATGAGGCATTGAAGAGGGTTG-3′; β-actin forward, 5′-CATGTACGTTGCTATCCAGGC-3′ and reverse, 5′-CTCCTTAATGTCACGCACGAT-3′. PCR reaction with β-actin primers was used as an internal control. And the relative transcriptional level of *GSDMC* was normalized to β-actin. After the cycle threshold (Cq) value (power amplification knee point) was achieved, we used the 2^−ΔΔCq^ method to determine the relative expression levels ([@b23-mmr-21-01-0360]). The specificity of amplification products was confirmed by the melting curve analysis. All experiments were repeated at least three times.

### Statistical analyses

The differential expression of *GSDMC* between normal and LUAD samples was examined by the Student\'s t-test with SPSS 12.0 software (SPSS, Inc.). Wilcoxon\'s and Chi-square tests were performed to study associations between *GSDMC* molecular profiles and clinical pathologic characteristics. The significance of the difference between survival as determined by Kaplan-Meier curves was evaluated with the Logrank test. The correlation analysis was conducted by Pearson\'s correlation coefficient. The statistical differences were considered significant at a P-value of \<0.05.

Results
=======

### Identification of upregulated GSDMC in LUAD tissues and cell lines

Using data from several bioinformatic tools, molecular profiles of the GSDM family members were evaluated between LUAD tissues and adjacent normal lung tissues. The heatmap of data from UALCAN showed that *GSDMA, GSDMB, GSDMC* and *DFNB59* were all upregulated in LUAD compared with the levels in adjacent normal tissues ([Fig. 1A](#f1-mmr-21-01-0360){ref-type="fig"}). However, in a dataset (Selamat Lung) extracted from Oncomine, only *GSDMB, GSDMC* and *DFNA5* were found to be significantly highly expressed in tumor tissues ([Fig. 1B](#f1-mmr-21-01-0360){ref-type="fig"}). Another heatmap result from GEPIA showed that *GSDMA, GSDMB* and *GSDMC* were significantly overexpressed in LUAD tissues ([Fig. 1C](#f1-mmr-21-01-0360){ref-type="fig"}). These findings collectively revealed that both *GSDMB* and *GSDMC* were consistently upregulated in LUAD patients. To verify these dysregulations, their expression was further detected in LUAD tissues using the IHC data from Human Protein Atlas project. As shown in [Fig. 1D](#f1-mmr-21-01-0360){ref-type="fig"}, the IHC results revealed that moderate GSDMB expression and negative GSDMC expression could be observed in normal lung tissues. In comparison, among the 8 cases of LUAD tissues examined for GSDMB staining, 6 cases had negative expression, while the remaining 2 cases had weak intensity. Conversely, among the 11 cases of LUAD tissues examined for GSDMC staining, 4 cases had strong or moderate staining, while the remaining 7 cases had negative expression. All these findings together demonstrated that *GSDMC* is significantly upregulated in LUAD compared with adjacent normal tissues.

Next, the expression level of *GSDMC* was established in lung cancer cells. By exploring the CCLE database, a total of 75 LUAD cell lines with corresponding *GSDMC* expression values were finally selected. The heatmap data indicated that more than half of the bands were red, revealing the overexpressed *GSDMC* level in LUAD cells ([Fig. 2A](#f2-mmr-21-01-0360){ref-type="fig"}, [Table SI](#SD1-mmr-21-01-0360){ref-type="supplementary-material"}). We also compared *GSDMC* expression levels in cancer cells with different metastatic abilities. The phenotypic differences in LUAD cells are summarized in [Table SII](#SD1-mmr-21-01-0360){ref-type="supplementary-material"}. Expectedly, the expression level of *GSDMC* was significantly upregulated in metastatic LUAD cells ([Fig. 2B](#f2-mmr-21-01-0360){ref-type="fig"}). Then, the expression of *GSDMC* was further determined in radio-resistant lung cancer cells. The qPCR analysis showed that *GSDMC* was obviously upregulated in radio-resistant LUAD cells (NCIH358R and A549R), compared with the parental cells (NCIH358 anc A549) ([Fig. 2C](#f2-mmr-21-01-0360){ref-type="fig"}). Taken together, the above-mentioned data collectively demonstrated that overexpression of *GSDMC* acts as a promising oncogenic biomarker in LUAD.

### Preserved GSDMC expression is an independent indicator for LUAD patients

Kaplan-Meier curves showed that the LUAD patients with low *GSDMC* expression had significantly better first progression (FP) (P=0.00001) and overall survival (OS) (P=0.0077) ([Fig. 3A and B](#f3-mmr-21-01-0360){ref-type="fig"}). In addition, although patients with low *GSDMC* expression had a better post-progression survival (PPS), no statistical significance was achieved (P=0.22) ([Fig. 3C](#f3-mmr-21-01-0360){ref-type="fig"}). The associations between clinical pathological characteristics and *GSDMC* expression profiles are summarized in [Table II](#tII-mmr-21-01-0360){ref-type="table"}. The findings showed that, compared with the patients with low *GSDMC* expression, the LUAD patients with high *GSDMC* expression had a significantly higher ratio of the *KRAS* mutation (22/45, 48.9% vs. 1/18, 5.6%; P=0.001) and a longer history of cigarette smoking (P=0.012) ([Table II](#tII-mmr-21-01-0360){ref-type="table"}).

### DNA hypomethylation has a negative effect on GSDMC expression

The methylation status of *GSDMC* DNA was measured using an Illumina 450K Infinium methylation chip (Illumina, Inc.). The results from the MethHC web-tool showed that the *GSDMC* methylation level was significantly lower in LUAD tissues (P\<0.05) ([Fig. 4A](#f4-mmr-21-01-0360){ref-type="fig"}). A significantly negative correlation was found between *GSDMC* expression and its DNA methylation status (Pearson\'s r=−0.136, P\<0.001) ([Fig. 4B](#f4-mmr-21-01-0360){ref-type="fig"}). Meanwhile, regression analysis from the MEXPRESS database also confirmed the negative relation between *GSDMC* expression and the methylation values of two CpG sites (cg05316065 and cg26073844) in LUAD cases (Pearson\'s r=−0.175, P\<0.001 and Pearson\'s r=−0.141, P\<0.01, respectively) ([Fig. 4C](#f4-mmr-21-01-0360){ref-type="fig"}). Based on its obvious significance, the CpG site, cg05316065, has been chosen to access the methylation status of *GSDMC* DNA on the LUAD patient clinical prognosis. Chi-square analysis showed that the patients with high methylation values of the CpG site (cg05316065) had a significantly higher Karnofsky performance score (KPS), an easy-to-use prognostic model for prognosis ([@b24-mmr-21-01-0360],[@b25-mmr-21-01-0360]). Moreover, the results suggested that the cases with high methylation values of *GSDMC* had a longer OS and disease-free survival (DFS), although there were no significant differences ([Table III](#tIII-mmr-21-01-0360){ref-type="table"}).

Next, the relationship between *GSDMC* expression and its CNA/mutation status was also evaluated. We found that 581 samples among the 584 sequenced LUAD patients had CNAs measured, while only 45 samples (8%) had an obvious copy number change (+2 high level amplification altered) ([Fig. 5A](#f5-mmr-21-01-0360){ref-type="fig"}). Additionally, the somatic mutation in *GSDMC* DNA was only found in 8 cases (1.4%), with unknown significance ([Fig. 5B](#f5-mmr-21-01-0360){ref-type="fig"}). Thus, the CNA/mutation status did not influence *GSDMC* expression distinctly.

### Functional enrichment analysis of GSDMC-associated co-expression genes in LUAD patients

From a TCGA-LUAD dataset (TCGA, Provisional) of cBioPortal, 13,446 genes that were co-expressed with *GSDMC* were identified in the LUAD samples. Then, using the criteria of \|log~2~(fold change)\| ^3^2 and P-value \<0.05, 215 genes were preliminarily validated as *GSDMC*-associated co-differentially expressed genes (co-DEGs) ([Table SIII](#SD1-mmr-21-01-0360){ref-type="supplementary-material"}). These co-DEGs between the altered and unaltered *GSDMC* expression group are shown as a volcano plot ([Fig. 6A](#f6-mmr-21-01-0360){ref-type="fig"}). Next, GO and KEGG analyses were performed to clarify their biological function. The biological processes enrichment analysis showed that these co-DEGs were mainly correlated with biological regulation and metabolic processes. The cellular component of these co-DEGs was mainly enriched in the membrane and the nucleus. For molecular function analysis, these co-DEGs were enriched primarily in terms of protein binding ([Fig. 6B](#f6-mmr-21-01-0360){ref-type="fig"}). The KEGG pathway, annotated by the DAVID bioinformatics resource, indicated that these co-DEGs were mainly enriched in cell cycle regulation (hsa04110) ([Fig. 6C](#f6-mmr-21-01-0360){ref-type="fig"}).

Discussion
==========

Research indicates that dysregulated *GSDMC* is associated with multiple cancer biological behaviors. Watabe *et al* ([@b26-mmr-21-01-0360]) suggested that *GSDMC* overexpression promotes cell metastasis in B16 melanoma cells. In colorectal cancer cells, enforced *GSDMC* expression was found to enhance cell proliferation and tumorigenesis by suppressing TGFBR2 activity ([@b8-mmr-21-01-0360]). However, in gastric cancer cells, *GSDMC* was found to exert obvious cell-growth inhibition activity, functioning as a potential tumor suppressor ([@b27-mmr-21-01-0360]). These findings collectively demonstrate that the detailed functional roles of *GSDMC* are tissue-specific.

By using several public databases, our present study presented the expression profiles of GSDM superfamily members in LUAD, which revealed that *GSDMC* is obviously upregulated in LUAD tissues and cell lines. We also found that the LUAD patients with higher *GSDMC* expression presented with significant KRAS mutation status. Studies have revealed that patient prognosis after LUAD diagnosis is usually poor, and current treatment strategies derived from primary LUAD seem to be largely inefficacious ([@b28-mmr-21-01-0360]). Next, we detected the potential influence of *GSDMC* expression on the prognostic markers of LUAD patients, in terms of first progression (FP), overall survival (OS) and post-progression survival (PPS). Kaplan-Meier curves showed significantly better FP and OS in the lower *GSDMC* staining group, but no statistical difference in PPS cases with different *GSDMC* expression. These unexpected findings may be due to the small sample size and may need to be further examined in future studies. The following analysis of the association between *GSDMC* profiles and clinicopathological parameters further support that preserved *GSDMC* expression could act as an independent prognostic indicator for LUAD patients.

Research has revealed that epigenetic alterations (such as DNA hypomethylation) and genetic mutations have key functions in modulating transcription of important oncogenes in several types of human carcinomas, including LUAD ([@b29-mmr-21-01-0360]--[@b33-mmr-21-01-0360]). For example, Upchurch *et al* ([@b34-mmr-21-01-0360]) found that aberrant promoter hypomethylation frequently affected the expression levels of several oncogenes in hematologic malignancies. Preferentially expressed phosphoribosylaminoimidazole carboxylase (PAICS) has been confirmed as a major tumor promoter in LUAD, which is frequently activated by promoter DNA hypomethylation ([@b33-mmr-21-01-0360]). Cancer/testis antigen 45 (CT45) has been confirmed to be associated with disease progression of epithelial ovarian cancer, which is frequently activated by promoter DNA hypomethylation ([@b35-mmr-21-01-0360]). Unexpectedly, the CNAs in *CT45* DNA did not obviously influence its expression ([@b35-mmr-21-01-0360]). In addition, Wang *et al* ([@b29-mmr-21-01-0360]) demonstrated that tumor-suppressive activity by *adenosine deaminase RNA-specific B1 (ADARB1)* overexpression is a consequence of DNA demethylation signaling. Inactivation of DNA methylation using DNA methyltransferase inhibitors markedly enhanced the *ADARB1*-mediation metastatic inhibition of LUAD cells. Here, using the data from an Illumina 450K Infinium methylation chip, we identified that *GSDMC* was hypomethylated in LUAD samples compared with that in normal lung samples (P\<0.05) ([Fig. 4A](#f4-mmr-21-01-0360){ref-type="fig"}). In addition, a significant negative correlation was found between *GSDMC* expression and its DNA methylation status in all LUAD cases (Pearson\'s r=−0.136). Meanwhile, the results from the MEXPRESS database confirmed that the expression of *GSDMC* was negatively correlated to the methylation values of two CpG sites (cg05316065 and cg26073844) in its promoter region (Pearson\'s r=−0.175 and −0.141, respectively). Although this is the first study to identify these two hypomethylated CpG sites in *GSDMC* and to demonstrate several advances in indicating their functions in LUAD tumorigenesis, many of the functional mechanisms remain poorly understood; particularly in terms of their roles in cancer metastasis, risk index and therapeutic response. Moreover, in this report, the LUAD patients with longer OS also had higher *GSDMC* methylation values. In comparison, *GSDMC* DNA CNAs and somatic mutation were not frequent events, and might not obviously affect the transcriptional level. Thus, these experiments confirmed the important functions of DNA hypomethylation for the overexpression of *GSDMC* in LUAD biological processes.

Alterations in cell cycle regulation have been well-described to date in human carcinogenesis as they are known to play pivotal roles in cell differentiation and growth. Identifying the changes in cell cycle checkpoints is essential to the regulation of cell cycle processes and the maintenance of genome integrity. Abnormal activation of oncogenes or various cancer therapeutic strategies could evoke cell cycle arrest in malignant cells, thereby interfering with tumor formation or progression ([@b36-mmr-21-01-0360]). Moreover, studies have shown that tight temporal control of cell cycle checkpoints has a potential application in clinical practice. The pharmacological inhibitors that target cell cycle checkpoints have the potential to provoke the synthetic lethality of anticancer therapeutics and disrupt the cancerous phenotype ([@b37-mmr-21-01-0360]). Esophageal squamous cell carcinoma cells treated with chemotherapeutic agents have impaired cell cycle progression and DNA damage repair by promoting the accumulation of GSDME around the cytoplasm ([@b38-mmr-21-01-0360]). In our study, the detailed molecular interactions between *GSDMC* and its co-expressed genes were not well-illuminated; however, the GO and KEGG analyses that were constructed identified the function of *GSDMC* to some extent. Using the gene-annotation enrichment analysis, the main functional pathway of the *GSDMC* co-expressed genes was confirmed to be cell cycle regulation. However, no relevant studies have demonstrated the roles and mechanisms of *GSDMC* in cell cycle modulation. Therefore, further research is required to clarify the detailed functions of *GSDMC* in LUAD biology.

In conclusion, collectively, our present study revealed that *GSDMC* is significantly overexpressed in LUAD tissues and cell lines. We also found that upregulated *GSDMC* expression could act as an independent predictor for the poor prognosis of LUAD patients. Mechanistically, *GSDMC* expression may be modulated by DNA hypomethylation in LUAD cells.
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###### 

*GSDMC* is upregulated in LUAD tissues compared with normal lung tissues. (A-C) Heatmaps of the expression of GSDM superfamily genes (*GSDMA, GSDMB, GSDMC, GSDMD, DFNA5* and *DFNB59*) between LUAD and paired normal samples. The results were generated by reanalysis of the data from UALCAN, Oncomine and GEPIA. (D) Representative GSDMB and GSDMC immunohistochemical (IHC) staining in normal lung and LUAD tissues. Image credit: The Human Protein Atlas Project. GSDM, gasdermin; LUAD, lung adenocarcinoma; UALCAN, University of Alabama Cancer Database; GEPIA, Gene Expression Profiling Interactive Analysis.
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![Identification of the overexpression of *GSDMC* in LUAD cells. (A) Heatmap for expression of *GSDMC* in LUAD cell lines. Red represents higher expression of *GSDMC* and blue represents lower expression. Each bar on the right part represents the expression of *GSDMC* in a lung cell line (contains 75 cell lines). (B) The expression levels of *GSDMC* in LUAD cell lines with different metastatic capability. (C) qPCR of the mRNA expression levels of *GSDMC* in radio-resistant LUAD cells. P≥0.05 indicates a significant difference. *GSDMC*, gasdermin C; LUAD, lung adenocarcinoma.](MMR-21-01-0360-g02){#f2-mmr-21-01-0360}

![Kaplan-Meier curves of FP, OS and PPS in LUAD patients with different *GSDMC* expression. (A-C) The Kaplan-Meier Plotter platform was used to quickly confirm disease prognosis, such as FP, (A) OS (B) and PPS. (C) The Cancer Genome Atlas (TCGA) clinical data were used to categorize LUAD patients according to their expression levels of *GSDMC*. *GSDMC*, gasdermin C; LUAD, lung adenocarcinoma; FP, first progression; OS, overall survival; PPS, post-progression survival.](MMR-21-01-0360-g03){#f3-mmr-21-01-0360}

![DNA hypomethylation may be a mechanism of the overexpression of *GSDMC* expression in LUAD. (A) Box-plot showing the methylation values between LUAD and normal lung tissues. (B) Regression analysis of the correlation between *GSDMC* expression and its DNA methylation in LUAD cases. (C) Regression analysis of the correlation between *GSDMC* expression and the DNA methylation of CpG sites in LUAD cases. *GSDMC*, gasdermin C; LUAD, lung adenocarcinoma.](MMR-21-01-0360-g04){#f4-mmr-21-01-0360}

![*GSDMC* DNA CNAs and mutations. (A) Heatmap showing the correlation between GSDMC expression and its DNA CNAs. The data indicated that GSDMC expression was altered only in 8% of cases with CNAs (+2 high level amplification altered). (B) Heatmap showing the correlation between *GSDMC* expression and its DNA mutations in LUAD patients. *GSDMC*, gasdermin C; LUAD, lung adenocarcinoma; CNAs, copy number alterations.](MMR-21-01-0360-g05){#f5-mmr-21-01-0360}

![Function of enrichment analysis concerning *GSDMC*-related genes in LUAD patients. (A) A volcano plot showing *GSDMC*-associated co-expressed genes between the altered and unaltered *GSDMC* expression group in the selected TCGA-LUAD data (TCGA, Provisional). (B) The top significant GO biological process enrichments, including biological regulation and metabolic processes. The top dysregulated cellular component in LUAD is the membrane and nucleus. The GO enrichment analysis of molecular function is primarily enriched in terms of protein binding. (C) KEGG pathway analyses of *GSDMC*-related co-DEGs in the selected TCGA-LUAD data (TCGA, Provisional). *GSDMC*, gasdermin C; LUAD, lung adenocarcinoma; TCGA, The Cancer Genome Atlas; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-21-01-0360-g06){#f6-mmr-21-01-0360}

###### 

Bioinformatic tools used to analyze the roles of *GSDMC* in LUAD biology.

  Database                      URL                                              (Refs.)
  ----------------------------- ------------------------------------------------ -------------------------
  GEPIA                         <http://gepia.cancer-pku.cn/>                    ([@b9-mmr-21-01-0360])
  UALCAN                        <http://ualcan.path.uab.edu/index.html>          ([@b10-mmr-21-01-0360])
  Oncomine                      <https://www.oncomine.com/resource/login.html>   ([@b11-mmr-21-01-0360])
  CCLE                          <https://portals.broadinstitute.org/ccle>        ([@b12-mmr-21-01-0360])
  Human Protein Atlas project   <http://www.proteinatlas.org/>                   ([@b13-mmr-21-01-0360])
  cBioPortal                    <http://www.cbioportal.org/>                     ([@b14-mmr-21-01-0360])
  Kaplan-Meier Plotter          <http://kmplot.com/analysis/>                    ([@b15-mmr-21-01-0360])
  MethHC                        <http://methhc.mbc.nctu.edu.tw/php/index.php>    ([@b16-mmr-21-01-0360])
  MEXPRESS                      <http://mexpress.be/>                            ([@b17-mmr-21-01-0360])
  DAVID                         <https://david.ncifcrf.gov/>                     ([@b18-mmr-21-01-0360])
  WebGestalt                    <http://www.webgestalt.org/option.php>           ([@b19-mmr-21-01-0360])

GSDMC, gasdermin C; LUAD, lung adenocarcinoma; GEPIA, Gene Expression Profiling Interactive Analysis; CCLE, Cancer Cell Line Encyclopedia; DAVID, Database for Annotation, Visualization and Integration Discovery.

###### 

Expression of *GSDMC* in the TCGA-LUAD datasets.

  Patient characteristics                        No. of patients (%)   High expression n (%)   Low expression n (%)   P-value
  ---------------------------------------------- --------------------- ----------------------- ---------------------- -----------
  Sex (N=515)                                                                                                         0.389
    Male                                         240 (46.6)            158 (48.0)              82 (44.1)              
    Female                                       275 (53.4)            171 (52.0)              104 (55.9)             
  Lymph node stage (N=514)                                                                                            0.326
    N0                                           332 (64.6)            215 (65.5)              117 (62.9)             
    N1                                           95 (18.5)             63 (19.2)               32 (17.2)              
    N2                                           74 (14.4)             44 (13.4)               30 (16.1)              
    N3                                           2 (0.4)               0 (0.0)                 2 (1.1)                
    NX                                           11 (2.1)              6 (1.8)                 5 (2.7)                
  Metastasis stage (N=511)                                                                                            0.922
    M0                                           345 (67.5)            222 (68.1)              123 (66.5)             
    M1                                           25 (4.9)              16 (4.9)                9 (4.9)                
    MX                                           141 (27.6)            88 (27.0)               53 (28.6)              
  Tumor stage (N=515)                                                                                                 0.675
    T1                                           168 (32.6)            110 (33.4)              58 (31.2)              
    T2                                           278 (54.0)            175 (53.2)              103 (55.4)             
    T3                                           47 (9.1)              29 (8.8)                18 (9.7)               
    T4                                           19 (3.7)              14 (4.3)                5 (2.7)                
    TX                                           3 (0.6)               1 (0.3)                 2 (1.0)                
  Stage (N=507)                                                                                                       0.808
    I                                            276 (54.4)            175 (54.3)              101 (54.6)             
    II                                           121 (23.9)            80 (24.8)               41 (22.2)              
    III                                          84 (16.6)             50 (15.5)               34 (18.4)              
    IV                                           26 (5.1)              17 (5.3)                9 (4.9)                
  Race (N=448)                                                                                                        0.145
    Asian                                        8 (1.8)               3 (1.1)                 5 (3.0)                
    Black                                        53 (11.8)             29 (10.4)               24 (14.2)              
    Caucasian                                    387 (86.4)            247 (88.5)              140 (82.8)             
  Age (N=496) in years                                                                                                0.558
    20--40                                       2 (0.4)               2 (0.6)                 0 (0.0)                
    40--60                                       134 (27.0)            81 (25.6)               53 (29.4)              
    60--80                                       329 (66.3)            211 (66.8)              118 (65.6)             
    ≥80                                          31 (6.3)              22 (7.0)                9 (5.0)                
  *KRAS* mutation (N=63)                                                                                              **0.001**
    No                                           40 (63.5)             23 (51.1)               17 (94.4)              
    Yes                                          23 (36.5)             22 (48.9)               1 (5.6)                
  KPS (N=99)                                                                                                          0.908
    0--70                                        12 (12.1)             6 (11.8)                6 (12.5)               
    80                                           23 (23.2)             13 (25.5)               10 (20.8)              
    90                                           32 (32.3)             17 (33.3)               15 (31.3)              
    100                                          32 (32.3)             15 (29.4)               17 (35.4)              
  Cigarette smoking history, pack year (N=349)                                                                        0.012
    ≤5                                           7 (2.0)               5 (2.2)                 2 (1.6)                
    6--20                                        51 (14.6)             34 (15.0)               17 (13.8)              
    21--40                                       115 (33.0)            81 (35.8)               34 (27.6)              
    41--60                                       106 (30.4)            67 (29.6)               39 (31.7)              
    61--80                                       33 (9.5)              17 (7.5)                16 (13.0)              
    81--100                                      17 (4.9)              15 (6.6)                2 (1.6)                
    \>100                                        20 (5.7)              7 (3.1)                 13 (10.6)              

GSDMC, gasdermin C; LUAD, lung adenocarcinoma; KPS, Karnofsky performance scores; TCGA, The Cancer Genome Atlas. P-values presented in bold print indicate significant differences.

###### 

The cg05316065 methylation status of *GSDMC* in the TCGA-LUAD datasets.

                             cg05316065 methylation value                                                 
  -------------------------- ------------------------------ ---------------------- ---------------------- -----------
  Sex (N=447)                                                                                             **0.008**
    Male                     208 (46.5)                     118 (52.9)             90 (40.2)              
    Female                   239 (53.5)                     105 (47.1)             134 (59.8)             
  Lymph node stage (N=445)                                                                                0.317
    N0                       290 (65.2)                     149 (67.1)             141 (63.2)             
    N1                       82 (18.4)                      35 (15.8)              47 (21.1)              
    N2                       64 (14.4)                      35 (15.8)              29 (13.0)              
    NX                       9 (2.0)                        3 (1.4)                6 (2.7)                
  Metastasis stage (N=443)                                                                                0.701
    M0                       292 (65.9)                     143 (64.4)             149 (67.4)             
    M1                       19 (4.3)                       11 (5.0)               8 (3.6)                
    MX                       132 (29.8)                     68 (30.6)              64 (29.0)              
  Tumor stage (N=447)                                                                                     0.101
    T1                       150 (33.6)                     67 (30.0)              83 (37.1)              
    T2                       239 (53.5)                     119 (53.4)             120 (53.6)             
    T3                       39 (8.7)                       25 (11.2)              14 (6.3)               
    T4                       16 (3.6)                       11 (4.9)               5 (2.2)                
    TX                       3 (0.7)                        1 (0.4)                2 (0.9)                
  Stage (N=442)                                                                                           0.591
    I                        241 (54.5)                     118 (53.2)             123 (55.9)             
    II                       109 (24.7)                     52 (23.4)              57 (25.9)              
    III                      72 (16.3)                      41 (18.5)              31 (14.1)              
    IV                       20 (4.5)                       11 (5.0)               9 (4.1)                
  Race (N=399)                                                                                            0.813
    Asian                    6 (1.5)                        4 (2.0)                2 (1.0)                
    Black                    40 (10.0)                      20 (10.0)              20 (10.1)              
    Caucasian                353 (88.5)                     176 (88.0)             177 (88.9)             
  Age (N=428) in years                                                                                    0.522
    20--40                   0 (0.0)                        0 (0.0)                0 (0.0)                
    40--60                   119 (27.8)                     59 (27.2)              60 (28.4)              
    60--80                   280 (65.4)                     146 (67.3)             134 (63.5)             
    ≥80                      29 (6.8)                       12 (5.5)               17 (8.1)               
  *KRAS* mutation (N=61)                                                                                  0.979
    No                       38 (62.3)                      15 (62.5)              23 (62.2)              
    Yes                      23 (37.7)                      9 (37.5)               14 (37.7)              
  KPS (N=83)                                                                                              0.044
    0--70                    11 (13.3)                      4 (8.9)                7 (18.4)               
    80                       19 (22.9)                      11 (24.4)              8 (21.1)               
    90                       24 (28.9)                      9 (20.0)               15 (39.4)              
    100                      29 (34.9)                      21 (46.7)              8 (21.1)               
  Median DFS (95% CI)        33.44 (24.70--42.18)           33.44 (24.73--42.14)   30.39 (15.77--45.01)   0.823
  Median OS (95% CI)         49.24 (41.29--57.19)           50.3 (38.09--62.51)    49.21 (42.42--56.00)   0.921

GSDMC, gasdermin C; LUAD, lung adenocarcinoma; KPS, Karnofsky performance scores; TCGA, The Cancer Genome Atlas; DFS, disease-free survival; OS, overall survival; CI, confidence interval. P-values presented in bold print indicate significant differences.
